NEW YORK (360Dx) – Medosome Biotec said on Monday that it has received accreditation for its genetic testing laboratory from the College of American Pathologists.
The firm added that the CAP accreditation qualified it to receive a license from the Agency for Health Care Administration to operate a clinical laboratory in Florida, and to receive a CLIA Certificate of Accreditation from the Centers for Medicare and Medicaid Services.
Medosome Biotec said that it is developing a program for personalized medicine that involves genetic testing of patients for pharmaceutical drug compatibility and tolerance, and that a drug it is developing to treat a rare pediatric metabolism disorder is entering a Phase III clinical trial with the US Food and Drug Administration.
The firm added that its genetic test will provide physicians with dosing information so that children may be treated without harmful side effects from the drug.